Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies

November 10th 2023

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.

Ongoing Research on HER3-DXd in NSCLC

November 9th 2023

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss clinical trials evaluating the use of patritumab deruxtecan in patients with non–small cell lung cancer and remaining unmet needs.

ASCO Recommends Trilaciclib in Extensive-Stage Small Cell Lung Cancer in Guideline Update

November 6th 2023

In their updated guidelines for patients with small cell lung cancer (SCLC), ASCO has recommended the CDK4/6 inhibitor trilaciclib as a myeloid supportive agent for patients with untreated or previously treated extensive-stage SCLC who are receiving chemotherapy or chemoimmunotherapy.

Managing T-DXd Toxicities in Gastric Cancer

November 3rd 2023

Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.

Gastric Cancer Treatment: T-DXd

November 3rd 2023

A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.

Role of HER3-DXd in Advanced NSCLC Treatment Landscape

November 2nd 2023

Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.

NSCLC: Safety Outcomes from HERTHENA-Lung01

November 2nd 2023

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

EU Approval Sought for Encorafenib/Binimetinib in BRAF V600+ Advanced NSCLC

November 2nd 2023

The European Medicines Agency had validated a marketing authorization application seeking the approval of the combination of encorafenib and binimetinib for the treatment of adult patients with BRAF V600–mutant advanced non–small cell lung cancer.

VIC-1911 With/Without Sotorasib Under Investigation in KRAS G12C Inhibitor–Resistant and –Naïve NSCLC

November 2nd 2023

Sarah Goldberg, MD, MPH, highlights the mechanism of action of VIC-1911, expands on its ongoing investigation in the phase 1 trial, and sheds light on next steps planned for the agent’s investigation in KRAS G12C–mutant non–small cell lung cancer.

Dr Nieva on the Rationale for Investigating At-Home Atezolizumab Administration in NSCLC

November 1st 2023

Jorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.

Dr Shields on Updates in Upfront Systemic Therapy in ES-SCLC

November 1st 2023

Misty D. Shields, MD, PhD, discusses systemic therapy updates for patients with extensive-stage small cell lung cancer.

Dr Passaro on the Significance of the TROPION-Lung05 Trial of Dato-DXd in NSCLC

November 1st 2023

Antonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology, discusses the significance of data from the phase 2 TROPION-Lung05 trial of datopotamab deruxtecan in patients with non–small cell lung cancer.

Dr Liu on the Significance of T-DXd For Patients With HER2-Mutant NSCLC and Brain Metastases

October 31st 2023

Stephen V. Liu, MD, discusses the significance of using fam-trastuzumab deruxtecan-nxki in patients with HER2-mutant non–small cell lung cancer and brain metastases according to pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials.

FDA Grants Breakthrough Therapy Designation to Furmonertinib for EGFR Exon 20 Insertion+ NSCLC

October 31st 2023

The FDA has granted breakthrough therapy designation to furmonertinib for use as a potential therapeutic option in patients with previously untreated, locally advanced or metastatic nonsquamous non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Dato-DXd vs Docetaxel in Previously Treated Advanced/Metastatic Non–Small Cell Lung Cancer: Results of the Randomized Phase III Study TROPION-Lung01

October 31st 2023

Aaron Lisberg, MD, reviews data from the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.

Emerging Therapeutic Targets Shape Testing and Treatment Decisions in SCLC and NSCLC

October 31st 2023

Apar Kishor Ganti, MD, discusses molecular targets to test for in lung cancer; treatment approaches for small cell lung cancer; and immunotherapy options for patients with metastatic non–small cell lung cancer in the frontline setting and beyond.

Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431

October 31st 2023

Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.

Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib

October 31st 2023

Martin Dietrich, MD, PhD, presents key data from the phase 3 MARIPOSA-2 study, which investigated amivantamab plus chemotherapy, with or without lazertinib, versus chemotherapy in patients with EGFR-mutated advanced NSCLC who experienced disease progression on osimertinib.

Dr Le on the Efficacy of Osimertinib Plus Ramucirumab in EGFR-Mutant mNSCLC

October 28th 2023

Xiuning Le, MD, PhD, discusses findings from the interim analysis of the phase 2 RAMOSE trial in patients with TKI-naïve metastatic non–small cell lung cancer harboring EGFR mutations.

Dr Rotow on the Investigation of ABBV-637 Plus Osimertinib in EGFR-Mutated NSCLC

October 27th 2023

Julia Rotow, MD, discusses results from a first-in-human phase 1 study of the EGFR-targeting, BCL-XL–inhibiting antibody-drug conjugate ABBV-637 in combination with osimertinib in patients with relapsed/refractory, EGFR-mutated non–small cell lung cancer.